ClinicalTrials.gg
Active, not recruitingNCT05947058Updated Feb 13, 2026

Minimally Displaced Femoral Neck Fracture Pilot Study

An interventional study of Arthroplasty and Internal Fixation in Femoral Neck Fractures, sponsored by University of Maryland, Baltimore. Active, not recruiting at 12 sites in 3 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Femoral Neck Fractures with a site in United States — 7 open to participants now, 10 under way, none of them phase 3. Femoral Neck Fractures · United States.

Planned enrollment
17th of 23
40 · median 122
Started
2023
with 4 others
No phase
17 of 26
6 open now
Registered
22nd of 26
by date

Among the 26 studies in Femoral Neck Fractures with a site in United States, this one is the 17th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2023, is one of 17 with no phase, and was the 22nd registered.

Femoral Neck Fractures

207 studies on the registry are indexed under Femoral Neck Fractures; 40 are open to participants now.

Browse Femoral Neck Fractures studies →

Open to participants now

7 of the 26 studies in Femoral Neck Fractures with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Femoral Neck Fractures studies recruiting now, 16 (70%) set no upper age limit and 4 (17%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Femoral Neck Fractures with a site in United States, or all of them as a file.
02

Study summary

The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult patients ages 60 years or older with a low-energy minimally displaced femoral neck fracture (FNF) treated with surgery will be eligible to participate in the study. Patients will be randomized to one of two treatment groups, hip arthroplasty or internal fixation. Participants will be followed for 1 year.

Read the detailed description

Nearly half of all elderly hip fractures are femoral neck fractures (FNFs) and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this significant practice change remains lacking.

The eventual definitive trial has significant potential to change clinical practice and optimize patient outcomes for individuals that experience a minimally displaced FNF. Treating minimally displaced FNFs with arthroplasty, instead of internal fixation, would be a paradigm shift in clinical care. This pilot study will demonstrate feasibility of the definitive trial and be used to refine aspects of the study protocol as necessary. If feasibility is successfully demonstrated, the pilot activities will be considered a vanguard phase for the definitive clinical trial.

Adult patients ages 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery will be eligible to participate in the study. Patients will be randomized to receive either hip arthroplasty or internal fixation. Patients will be followed for 1 year, with visits occurring at 6 weeks, 4 months, 8 months, and 1 year after fracture. At each follow-up, mortality, ambulation, days at home, and health status will be collected.

The primary objective is to assess feasibility of the trial and to collect information to inform the design of the definitive trial. The feasibility outcomes will include participant enrollment, adherence to treatment allocation, data collection methods, and compliance with key aspects of the protocol.

03

Conditions studied

  • Femoral Neck Fractures

Keywords

  • Minimally Displaced Femoral Neck Fractures
  • Arthroplasty
  • Internal Fixation
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 60 years of age or older.
  • Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging (MRI).
  • Minimally displaced fracture that could be, in the judgment of the attending surgeon, optimally managed with either arthroplasty or in situ internal fixation without reduction.
  • Low energy injury mechanism defined as a fall from standing height.
  • obtained from patient or proxy.
  • Surgeons with expertise in total hip arthroplasty, hemiarthroplasty, and internal fixation are available to perform surgery. Note: Surgeons do not need to be experts in all techniques.

Exclusion criteria

Exclusion Criteria:

  • Unable to ambulate 10 feet pre-injury with any assistance.
  • Associated lower extremity injury that prevents post-operative weightbearing.
  • Retained hardware around the hip that precludes either study treatment.
  • Infection around the hip (soft tissue or bone).
  • Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
  • Patient is too ill, in the judgement of the attending surgeon, for internal fixation.
  • Patient is too ill, in the judgement of the attending surgeon, for arthroplasty.
  • Unable to obtain due to language barriers.
  • Problems, in the judgment of study personnel, with maintaining follow-up with the patient.
  • Currently enrolled in a study that does not permit co-enrollment.
  • Prior enrollment in the trial.
  • Other reason to exclude the patient, as approved by the Methods Centre.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arthroplasty

    A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. We recommend surgeons consider a total hip arthroplasty for younger active, independent participants; conversely, a hemiarthroplasty is recommended for more frail, lower-demand participants. Similarly, cemented arthroplasty for older adult participants is also recommended. The surgical approach and the use of post-operative hip precautions will be determined by the treating surgeon.

    Procedure: Arthroplasty

  • Active comparator
    Internal Fixation

    Based on the fracture displacement eligibility criteria, minimal or no reduction is expected during the surgical procedure. However, the treating surgeon will be allowed to perform fracture reduction maneuvers if desired. Fixed angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. If using multiple cancellous screws, an inverted triangle or similar screw pattern is recommended. Fixed angle devices, such as a sliding hip screw (with or without an anti-rotation screw) or newer multi-screw fixed angle devices will also be permitted. Internal fixation constructs combining cancellous screws and fixed angle devices will be permitted.

    Procedure: Internal Fixation

Interventions

  • ProcedureArthroplasty

    The type of hip prothesis (hemi or total; cemented or uncemented) will be at the discretion of the treating surgeon.

  • ProcedureInternal Fixation

    Both fixed angle devices and multiple screws will be permitted for the internal fixation group.

06

What researchers measure

Primary outcomes

  1. Feasibility of Participant Enrollment

    Participant enrollment will be assessed by monitoring screening and enrollment metrics, including: * Proportion of clinical sites initiated and able to screen consecutive patients with minimally displaced FNF * Proportion of patients who are screened for eligibility to participate in the trial * Proportion of patients who meet the eligibility criteria * Proportion of patients who provide informed consent * Proportion of time required to enroll at least four participants per clinical site * Proportion of reasons for exclusion.

    Time frame: 12 months

  2. Feasibility of Treatment Allocation

    Feasibility of the treatment allocation will be assessed using the following metrics: * Adherence to arthroplasty treatment allocation * Adherence to internal fixation treatment allocation

    Time frame: 12 months

  3. Refine Data Collection Methods

    To refine the data collection methods, the following metrics will be reviewed: * Proportion of participants with missing data * Review of missing data to identify data fields that are not feasible to collect * Data errors to identify ways to improve the flow of the case report forms (CRFs) and data collection

    Time frame: 12 months

  4. Assess Protocol Compliance

    The following metrics will be used to assess compliance with the protocol: * Proportion of randomization errors * Proportion of participants who complete each follow-up visit * Proportion of participants who withdraw from the trial (withdrawal of consent) * Proportion of participants who cannot be located (loss to follow-up)

    Time frame: 12 months

07

Study locations

12 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 63 non-industry interventional studies with no phase under Femoral Neck Fractures, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 37 months is below that.

Counting every sponsor, half of 69 studies reached it within 46 months; a quarter within 25 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jul 17, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05947058
Responsible party
Mark Gage (Associate Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Jul 17, 2023
Start date
Nov 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Gerard Slobogean, MD
principal investigator · University of Maryland, Baltimore
Sheila Sprague, PhD
principal investigator · McMaster University
Joseph Patterson, MD
principal investigator · University of Southern California

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion